Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080017
Chunk: 60

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 60
---
 306 |     |          |  2,780.00 |     |                  |               2.12 |
| September 2024 Series C Common Warrants |     |          |   4,088 |     |          |      0.80 |     |                  |               2.71 |
| December 2024 Common Warrants           |     |          |   4,203 |     |          |    112.20 |     |                  |               2.98 |
| January 2025 Common Warrants            |     |          |   8,193 |     |          |    116.40 |     |                  |               3.02 |
| February 2025 Pre-funded Warrants       |     |          |  10,787 |     |          |     0.002 |     |                  | No expiration date |
| February 2025 Common Warrants           |     |          | 127,551 |     |          |     39.20 |     |                  |               4.61 |
| Outstanding as of June 30, 2025         |     |          | 159,724 |     | $        |    707.39 |     |                  |               4.40 |

<div align='center'>26</div>

NOTE 10 – FAIR VALUE MEASUREMENTS

Investment in equity securities

On
April 22, 2025, pursuant to the Fourth Securities Purchase Agreement, the Company issued and sold, and the investors purchased, in a
private placement (the “Fourth PIPE Financing”), 6,250 shares of its Series D Preferred Stock to investors in exchange for
the receipt of 1,000,279 shares of the Stella Series D Preferred Stock, in which a portion of the Stella Series D Preferred Stock was
owned by a related party investor (see Note 13). The exchange of shares was in lieu of cash, the cost of which is included in investment
in equity securities on the accompanying unaudited condensed balance sheet as of June 30, 2025. The fair value of Stella’s Series
D Preferred Stock received was determined to be $500,000 as of the transaction date, based on the subsequent sale of the 1,000,279 Stella
Series D Preferred Stock $500,000 in cash, pursuant to a Stock Purchase Agreement dated August 20, 2025 (see Note 14). Accordingly, the